Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

PURPOSE: Camrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. We aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Li, Jiang, Yi-Zhou, Wu, Song-Yang, Wu, Jiong, Di, Gen-Hong, Liu, Guang-Yu, Yu, Ke-Da, Fan, Lei, Li, Jun-Jie, Hou, Yi-Feng, Hu, Zhen, Chen, Can-Ming, Huang, Xiao-Yan, Cao, A-Yong, Hu, Xin, Zhao, Shen, Ma, Xiao-Yan, Xu, Ying, Sun, Xiang-Jie, Chai, Wen-Jun, Guo, Xiaomao, Chen, Xizi, Xu, Yanhui, Zhu, Xiao-Yu, Zou, Jian-Jun, Yang, Wen-Tao, Wang, Zhong-Hua, Shao, Zhi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365373/
https://www.ncbi.nlm.nih.gov/pubmed/35247906
http://dx.doi.org/10.1158/1078-0432.CCR-21-4313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365373/
https://www.ncbi.nlm.nih.gov/pubmed/35247906
http://dx.doi.org/10.1158/1078-0432.CCR-21-4313

Ejemplares similares